Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
13.61
+0.11 (0.81%)
At close: Apr 28, 2026, 4:00 PM EDT
13.61
0.00 (0.00%)
Pre-market: Apr 29, 2026, 7:22 AM EDT
Viridian Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 70.85 | 0.3 | 0.31 | 1.77 | 2.96 | |
| Revenue Growth (YoY) | 23359.93% | -3.82% | -82.28% | -40.20% | 182.19% | |
| Cost of Revenue | 338.93 | 238.25 | 159.77 | 100.89 | 56.89 | |
| Gross Profit | -268.08 | -237.95 | -159.45 | -99.12 | -53.92 | |
| Selling, General & Admin | 95.32 | 61.08 | 95 | 35.18 | 25.81 | |
| Operating Expenses | 95.32 | 61.08 | 95 | 35.18 | 25.81 | |
| Operating Income | -363.4 | -299.04 | -254.45 | -134.3 | -79.73 | |
| Interest Expense | -4.95 | -2.2 | -1.33 | -0.49 | -0 | |
| Interest & Investment Income | 27.4 | 31.6 | 18.24 | 4.92 | 0.32 | |
| Other Non Operating Income (Expenses) | -1.66 | -0.31 | -0.19 | - | - | |
| EBT Excluding Unusual Items | -342.6 | -269.95 | -237.73 | -129.87 | -79.41 | |
| Pretax Income | -342.6 | -269.95 | -237.73 | -129.87 | -79.41 | |
| Net Income | -342.6 | -269.95 | -237.73 | -129.87 | -79.41 | |
| Preferred Dividends & Other Adjustments | -60.67 | -61.39 | -62.73 | -42.83 | - | |
| Net Income to Common | -281.93 | -208.56 | -175.01 | -87.04 | -79.41 | |
| Shares Outstanding (Basic) | 85 | 68 | 45 | 32 | 12 | |
| Shares Outstanding (Diluted) | 85 | 68 | 45 | 32 | 12 | |
| Shares Change (YoY) | 24.92% | 51.68% | 39.48% | 169.22% | 235.07% | |
| EPS (Basic) | -3.32 | -3.07 | -3.91 | -2.71 | -6.66 | |
| EPS (Diluted) | -3.32 | -3.07 | -3.91 | -2.71 | -6.66 | |
| Free Cash Flow | -276.89 | -232.83 | -185.07 | -94.64 | -54.92 | |
| Free Cash Flow Per Share | -3.27 | -3.43 | -4.13 | -2.95 | -4.61 | |
| Operating Margin | -512.91% | -99018.21% | -81035.03% | -7579.23% | -2690.79% | |
| Profit Margin | -397.93% | -69059.60% | -55734.71% | -4912.13% | -2680.15% | |
| Free Cash Flow Margin | -390.81% | -77096.03% | -58938.85% | -5340.58% | -1853.49% | |
| EBITDA | -362.94 | -298.5 | -253.93 | -134.05 | -79.61 | |
| D&A For EBITDA | 0.46 | 0.54 | 0.52 | 0.26 | 0.12 | |
| EBIT | -363.4 | -299.04 | -254.45 | -134.3 | -79.73 | |
| Revenue as Reported | 70.85 | 0.3 | 0.31 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.